PMID- 38143548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231225
IS  - 1524-5012 (Print)
IS  - 2831-4107 (Electronic)
IS  - 1524-5012 (Linking)
VI  - 23
IP  - 4
DP  - 2023 Winter
TI  - Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
PG  - 315-328
LID - 10.31486/toj.23.0076 [doi]
AB  - Background: Anxiety disorders are commonly diagnosed and cause substantial 
      functional impairment. A mixture of pharmacologic and psychosocial treatments 
      currently exists, but these treatments are not always tolerable and effective. 
      For patients with anxiety resistant to standard therapy, psychedelics may be a 
      promising alternative. This review assesses the therapeutic benefits and safety 
      of psychedelics in treating anxiety disorders. Methods: We searched PubMed, 
      Embase, PsycInfo, and CINAHL for clinical trials investigating psychedelics in 
      patients with clinician-diagnosed generalized anxiety disorder, social anxiety 
      disorder, specific phobia, separation anxiety disorder, selective mutism, panic 
      disorder, agoraphobia, and anxiety attributable to another medical condition. We 
      analyzed data from 9 independent psychedelic-assisted trials testing ayahuasca (1 
      study), ketamine (4 studies), lysergic acid diethylamide (LSD) (2 studies), 
      3,4-methylenedioxymethamphetamine (MDMA) (1 study), and psilocybin (1 study). 
      Efficacy was assessed by measuring the change in outcome measures and the quality 
      of life from baseline. Results: The reviewed studies demonstrated encouraging 
      efficacy in reducing anxiety symptoms, increasing self-perception, and increasing 
      social function in patients with generalized anxiety disorder, social anxiety 
      disorder, or anxiety attributable to another medical condition while establishing 
      feasibility and evidence of safety. For many patients, the therapeutic effects of 
      the psychedelic treatment lasted weeks, and no severe adverse events were 
      reported. Conclusion: Based on the evidence of symptom reduction and safety, the 
      current literature (2011 to 2021) shows that psychedelics could be considered for 
      treating clinician-diagnosed anxiety disorders. Psychedelics may provide an 
      alternative therapeutic option for patients resistant to current standard 
      treatments.
CI  - (c)2023 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Feulner, Leah
AU  - Feulner L
AD  - The University of Queensland Medical School, Ochsner Clinical School, New 
      Orleans, LA.
FAU - Sermchaiwong, Thanpicha
AU  - Sermchaiwong T
AD  - The University of Queensland Medical School, Ochsner Clinical School, New 
      Orleans, LA.
FAU - Rodland, Nathan
AU  - Rodland N
AD  - The University of Queensland Medical School, Ochsner Clinical School, New 
      Orleans, LA.
FAU - Galarneau, David
AU  - Galarneau D
AD  - The University of Queensland Medical School, Ochsner Clinical School, New 
      Orleans, LA.
AD  - Department of Psychiatry, Ochsner Clinic Foundation, New Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - Ochsner journal
JID - 101125795
PMC - PMC10741816
OTO - NOTNLM
OT  - Agents-psychedelic
OT  - LSD
OT  - MDMA
OT  - anxiety
OT  - ayahuasca
OT  - hallucinogens
OT  - ketamine
OT  - psilocybin
EDAT- 2023/12/25 06:42
MHDA- 2023/12/25 06:43
PMCR- 2023/12/01
CRDT- 2023/12/25 04:17
PHST- 2023/12/25 06:43 [medline]
PHST- 2023/12/25 06:42 [pubmed]
PHST- 2023/12/25 04:17 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - toj.23.0076 [pii]
AID - 10.31486/toj.23.0076 [doi]
PST - ppublish
SO  - Ochsner J. 2023 Winter;23(4):315-328. doi: 10.31486/toj.23.0076.